DS Biopharma proprietary bioactive lipid technology
The DS Biopharma (DS) pharmaceutical compounds are based on a proprietary bioactive lipid technology platform which includes semi-synthetic fatty acids.
The molecules in question are produced naturally in the human body in minute quantities and are proven to be crucial in the pathways of several conditions including metabolic disorders of the liver and fibrotic disorders such as non alcoholic steatohepatitis (NASH), inflammatory skin disorders (such as dermatitis) and chronic pulmonary disease (such as asthma).
There is no known effective way of increasing the body’s own physiological level of these lipid molecules but DS has successfully synthesised several of these compounds as active pharmaceutical ingredients (APIs) which can be delivered topically and/or orally.
A key advantage of these naturally occurring, bioactive lipid compounds is that in many cases they offer clinical advantages over existing treatments with regard to toxicity, tolerability and efficacy.